Global Human Microbiome Market: Snapshot

With ample unmet needs, the global market for human microbiome exhibits high potential of growth. The market is set to emerge as a lucrative business in the near future, thanks to the increasing emphasis on diagnosis and treatment of various underrated diseases. The worldwide human microbiome market will be US$2.2 bn in 2020. The lack of targeted drugs for specific conditions, such as ulcerative colitis and C.difficile infection across the world makes this market highly opportune for players to set their innovative drug ideas on the path to commercial success. Driven by these factors, the opportunity in this market is slated to rise at a CAGR of 9.80% between 2020 and 2024 and reach US$3.2 bn by the end of 2024.

Microbiome diagnostics and microbiome therapeutics are the two prominent sections of the global human microbiome market. Currently, the market is in the budding phase, with most of the therapies still being in preclinical or clinical (phase I or phase II) stage. The diagnosis technology is also in the development phase and the leading companies have begun to allocate funds for the research and development and the management of clinical studies for their innovative class of therapies. All these factors are likely to propel this market significantly over the next few years. The human microbiome therapeutics market is likely to report a CAGR of 9.20% during the period of 2020 to 2024, whereas the market for human microbiome diagnostics is anticipated to rise at an 8.60% CAGR between 2018 and 2024.

human microbiome diagnostics market


North America to Report Continued Leadership

North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America are the key regional markets for human microbiome across the world. Thanks to the presence of a state-of-art medical and healthcare industry and early adoption of technology, North America has occupied the top position in the global market. Researchers expect that the rising number of venture-capital funded start-ups and the increasing investments by leading players for research and development of drugs will support the North America market for human microbiome over the forthcoming years, ensuring its dominance. The human microbiome therapeutics market in North America is anticipated to report a rise at a CAGR of 9.10% between 2020 and 2024 while the region’s human microbiome diagnostics market will progress at an 8.80% CAGR from 2018 to 2024.

Europe, which acquired the second position in the global human microbiome market, is projected to maintain its position over the years to come. The U.K. and France have emerged as the key domestic markets for human microbiome in Europe. The high investments by companies in this domain are expected to boost both these domestic markets in the next few years. Apart from this, countries, such as Sweden and the Netherlands, are also anticipated to contribute well to the Europe market for human microbiome market in the near future.

Metagenomic Sequencing to Outpace 16s rRNA in Future

On the basis of technology, the global market for human microbiome is classified into 16s rRNA sequencing and metagenomic sequencing. Both the technology are equally popular platforms for detection in the microbiome-based diagnostics. However, the metagenomic sequencing segment is likely to surpass the 16s rRNA segment over the next few years, albeit by a small margin, as a large number of companies are opting for the diagnosis of a more comprehensive microbiome profile.

At the forefront of the global market for human microbiome are Vedanta Biosciences, Synthetic Biologics Inc., Seres Therapeutics, Second Genome, uBiome Inc., Rebiotix Inc., Osel Inc., MicroBiome Therapeutics LLC., Metabiomics Corp., Enterome Biosciences SA, and AO Biome LLC. Some of the other prominent participants in this market are Metabogen AB, Becton Dickinson & Co., Evelo Biosciences, ARTPred, MaaT Pharma, Blue Turtle Bio Technologies, Axial Therapeutics, Whole Biome, 4D Pharma, Symbiotix Therapies, Phi Therapeutics, Synlogic, and Biospherex LLC.

Global Human Microbiome Market: Overview

The human microbiome also known as microbiota is composed of population of microbes such as fungi, bacteria and archaea. These microbes reside on the surface or in the deep layers of skin in oral mucosa, the saliva, gastrointestinal tracts and in the conjunctiva. At present, extensive research is being conducted to discover the importance of these micro-organisms in maintaining immune systems and contributing to digestion of food.

Large number of microbes reside in the large intestine, with region of the human body having a distinct community of microbes dwelling. Studies are still in progress to understand the factors regulating microbial colonization in areas of the body that are just millimeters apart. The Human Microbiome Project (HMP) was launched in 2008 as a U.S. National Institute of Health. This was initiated with a goal of identifying and characterizing the microbes found within the healthy and diseases human body.

Global Human Microbiome Market: Scope of the Study

This report on the global human microbiome market analyzes the future prospects of the market. The market for diagnostics and therapeutics is independently analyzed as two separate markets within the report. The market for microbiome therapeutics is segmented based on therapeutic area and region, while the market for microbiome diagnostics is segmented on the basis of indication, technology and region.

It comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2018 and 2024 for diagnostics and 2020 to 2024 for therapeutics, along with the compound annual growth rate (CAGR %) from 2018/20 to 2024 are provided for all the segments.

Market related factors such as new product launches, drugs in the pipeline, industry-institute collaborations in research for finding a pertinent cure, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the global human microbiome market have been determined after a thorough analysis of past and present trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Human Microbiome Market: Segmentation

Based on indication, the global human microbiome diagnostics market has been segmented into Gastrointestinal and Metabolic disorders, Women’s Health, Cancer and Others. Gastrointestinal & metabolic disorders are likely to show most promising growth in the market owing to the higher unmet medical need for gut health disorders as well as a rise in population suffering from faulty- lifestyle based metabolic diseases.

Based on technology, the market has been segmented into 16s rRNA sequencing and metagenomic sequencing. Both the forms have been documented to have various advantages with regard to accurate testing and hence, both these segments garner nearly equal share of the overall diagnostics market during the forecast period. Based on therapeutic area, the market has been segmented into Gastrointestinal Disorders, Metabolic disorders, Women’s Health, Skin Disorders and Others. Other therapeutic areas include autoimmune disorders, infant health disorders, and rare diseases.

Geographically, the global human microbiome market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries. These include the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, the UAE, and South Africa. The competition landscape section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the human microbiome market.

Companies Mentioned in the Study

The report profiles major players in the human microbiome market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AOBiome LLC, Osel Inc., Seres Therapeutics, Second Genome, uBiome Inc., Metabiomics Corp., Rebiotix Inc., Vedanta Biosciences etc.

The global human microbiome market has been segmented as follows:

By Indication

  • Gastrointestinal and Metabolic Disorders
  • Women’s Health
  • Cancer
  • Others

By Technology

  • 16s rRNA Sequencing
  • Metagenomic Sequencing

By Therapeutic Area

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Women’s Health
  • Skin Disorders
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • UAE
    • South Africa
    • Rest of Middle East and Africa